For those who are hoping to commercialize a mass spec pattern-based cancer diagnostic in the near future, navigating the waters of FDA approval is not likely to be a clear-cut process. As Correlogic Systems discovered last month — when the FDA sent the company a letter warning that the ovarian cancer test it had licensed to clinical reference laboratories LabCorp and Quest may be subject to premarket review — it’s not enough to simply call your diagnostic a “home brew” and hope the FDA takes your word for it. (see PM 2-27-04).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.